|
- 现金
- 62111 元
- 精华
- 26
- 帖子
- 30441
- 注册时间
- 2009-10-5
- 最后登录
- 2022-12-28
|
Vir Biotechnology Announces Multiple Abstracts Highlighting New Hepatitis B Data Accepted for Presentation at the International Liver Congress™ 2022
GuruFocusNews
18 hours ago
SAN FRANCISCO, June 08, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. ( VIR) today announced that three abstracts highlighting data from its hepatitis B virus (HBV) program have been accepted for one oral and two poster presentations at the International Liver Congress™ 2022 (ILC), the Annual Meeting of the European Association for the Study of the Liver (EASL), taking place in London and online June 22-26.
The oral presentation will highlight new dose and duration data from a Phase 2 trial evaluating VIR-2218, an investigational HBV-targeting small interfering ribonucleic acid (siRNA) that mediates RNA interference, for the potential functional cure of chronic HBV infection.
One poster presentation will highlight dose-dependent durability data from a Phase 1 trial of VIR-3434, an investigational HBV-neutralizing monoclonal antibody designed to inhibit HBV entry into cells, reduce the number of virions and subviral particles in the blood, and potentially function as a therapeutic T cell vaccine. The second poster presentation will showcase preclinical in vivo data demonstrating that the combination of VIR-2218 plus VIR-3434 resulted in greater surface antigen reductions than monotherapy with either therapy.
Presentation details are as follows:
Oral Presentation:
Title: Longer treatment duration of monthly VIR-2218 results in deeper and more sustained reductions in hepatitis B surface antigen in participants with chronic hepatitis B infection (Abstract #644)
Session: Viral Hepatitis: Hepatitis B Emerging Therapies
Date: Saturday, June 25
Time: 8:00 - 9:30 a.m. BST (3:00 - 4:30 a.m. EDT)
Presenter: Young-Suk Lim, M.D., Ph.D., Professor, Department of Gastroenterology and Liver Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
Poster Presentations:
Title: Dose-dependent durability of hepatitis B surface antigen reductions following administration of a single dose of VIR-3434, a novel neutralizing vaccinal monoclonal antibody (Abstract #654; Poster #SAT434)
Date: Saturday, June 25
Time: 9:00 a.m. BST (4:00 a.m. EDT)
Presenter: Kosh Agarwal, M.D., Consultant Hepatologist and Transplant Physician at the Institute of Liver Studies at King’s College Hospital, and Clinical Director of the NIHR South London Clinical Research Network
Title: VIR-2218 plus VIR-3434 combination therapy reduces hepatitis B virus surface antigen levels in vivo (Abstract #3009; Poster #SAT357)
Date: Saturday, June 25
Time: 9:00 a.m. BST (4:00 a.m. EDT)
Presenter: Andrea Cathcart, Ph.D., Director, Clinical Virology, Vir Biotechnology
About Chronic Hepatitis B
Chronic hepatitis B virus (HBV) infection remains an urgent global public health challenge associated with significant morbidity and mortality. Approximately 300 million people around the world are living with HBV and about 900,000 die from HBV-associated complications each year. These patients are significantly underserved by existing therapies, with low functional cure rates, lifelong daily therapy and poor tolerability. Vir Biotechnology is working to achieve a functional cure for the millions of people with hepatitis B around the world through its broad and differentiated portfolio.
About VIR-2218
VIR-2218 is an investigational subcutaneously administered HBV-targeting siRNA that has the potential to stimulate an effective immune response and have direct antiviral activity against HBV. It is the first siRNA in the clinic to include Enhanced Stabilization Chemistry Plus (ESC+) technology designed to enhance stability and minimize off-target activity, which potentially can result in an increased therapeutic index. VIR-2218 is the first asset in the Company’s collaboration with Alnylam Pharmaceuticals, Inc. to enter clinical trials.
About VIR-3434
VIR-3434 is an investigational subcutaneously administered HBV-neutralizing monoclonal antibody designed to block entry of all 10 genotypes of HBV into hepatocytes and reduce the level of virions and subviral particles in the blood. VIR-3434, which incorporates Xencor’s Xtend™ and other Fc technologies, has been engineered to potentially function as a T-cell vaccine against HBV in infected patients, as well as to have an extended half-life. |
|
发表于 2022-6-19 14:36
